Meet the Team

Mireia Jofre-Bonet is Head of Research and Vice President of the Office of Health Economics, replacing Professor Nancy Devlin.

Mireia is an economist specialised in health economics. She has worked on a broad spectrum of health Economics subjects including Lifestyle and Health Behaviour Decision Making; topics in Industrial Organisation applied to the Health Care sector and Pharmaceutical Regulation; Willingness To Pay for Health Insurance Schemes by the informal sector in low and middle income countries; Environmental factors and children’s health and wellbeing (domestic violence, maternal working hours; intergenerational transmission of health & behaviours); Adaptation to Health States; and, Migration and adaptation.

Charlotte has over a decade of experience in communications and external affairs for global NGO’s and academia with a specialist focus on health and development. She is interested in maximising the impact of health economic research and health technology assessment (HTA) to build alliances to create a thriving ecosystem benefiting patients, the NHS, industry and the economy. She is currently focused on building strategic relationships across the sector to improve the UK’s ability to generate, attract and benefit from biomedical innovation.

Mikel’s current research interests are the economics of the pharmaceutical industry; including innovation and incentives for encouraging medical R&D, regulation of pharmaceutical markets and social welfare analysis, and competition and incentives for health care providers.

Simon started working at the OHE in 2019 after completing (with Distinction) a MSc in Health Policy (Health Economics) from the London School of Economics and Political Sciences (LSE) in 2018.

Patricia’s main areas of research are: health-related quality of life measures, subjective well-being, cost-effectiveness thresholds, estimation of health-related outcomes, health policy evaluation, adaptation to health states, ordered choice models and theory of preferences.

Leia Davies joined the OHE in December 2019 and provides administrative and logistical support to the team. 

Leia has previously worked for Royal Mail and MCA in administrative roles and has a background in the arts and events. 

Leia studied Philosophy and Fine Art and exhibits her artwork in her spare time. 

Isobel joined OHE in 2020. She has an undergraduate degree in Natural Sciences specialising in infectious diseases from the University of Cambridge and a Masters of Public Health (MPH) from Imperial College London. Her MPH research focussed on inequality in pharmaceutical innovation for infectious diseases and the impact of World Bank income classification on pharmaceutical innovation. She has completed internships at the World Health Organisation and Drugs for Neglected Diseases Initiative (DNDi) in Geneva where she worked on their Paediatric HIV and Hepatitis C programmes.

Grace’s areas of expertise include health technology appraisal, economic modelling and clinical guidelines. Grace is also interested in the economic evaluation of diagnostics and patient stratification, early stage modelling, and the economic evaluation of regenerative medicines and other high cost therapies. Grace has recently been appointed to NICE’s Clinical Guidelines Update Standing Committee, where she provides expert advice on the economic implications of NICE’s clinical guideline recommendations.

Jake joined OHE in June 2021 from the investment data and technology industry. Since joining, he has developed expertise in the economics of pharmaceutical innovation, quantitative patient preference research, and the effects of the COVID-19 pandemic on cancer services in the UK. Jake is also interested in economic epidemiology and healthcare systems in lower- and middle-income countries.

Gayathri joined OHE in 2020. She has had 7 years of industry experience in health technology assessment and market access. She holds an MSc in Economic Evaluation in Healthcare from City University, London and a BA in Economics from the University of Cambridge.

Margherita joined the OHE in December 2016 as Economist. Her work at the OHE has involved a number consulting projects, relating to different aspects of pharmaceutical R&D and HTA activities. She has experience in supporting the development of internal strategies for pharmaceutical companies in defining the value proposition of their pipeline (e.g. value frameworks) and the evidence generation processes during the product lifecycle.

Phill's research interests include the economics of the pharmaceutical market, the productivity and outputs of NICE, and benchmarking industry performance. He has extensive knowledge of, and experience with, data and other information used to understand the medicines market and performance of the pharmaceutical industry.

Priscila joined OHE is September 2021 as an OHE Fellow. She is currently studying an MSc in Economic Evaluation in Healthcare at City University London. Priscila was previously an associate at a healthcare communication firm, providing support for clients from all sub-sectors of healthcare. Priscila holds a BSc in Biomedical Sciences from King's College London, and has spent a year at the University of North Carolina at Chapel Hill as part of her degree.

Hannah joined OHE in September 2020 as an OHE Fellow after completing a MSc in Development Economics at the University of Sussex. Her dissertation focused on investigating the effect of different government responses on COVID-19 deaths. Hannah has previously obtained a BSc in Economics from the University of Exeter and is currently undertaking an MSc in Health Economics at City, University of London. She gained exposure to research and public policy through a summer internship at the Institute of Economic Affairs.

Chris has over 20 years of applied health economics experience in consulting and academia. His interests centre on the use of health economics to maximise the societal value of scarce healthcare resources, including the use of cost-effectiveness and cost-utility frameworks to evaluate value-for-money and stated preference methods to elicit patient and public values.